LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced on July 31, 2026, that it has entered into an agreement with the Venezuelan Institute for Scientific Research (IVIC) to develop a digital platform module intended to support access to designated laboratory and scientific services. The agreement is through LataMed AI's Venezuelan operating subsidiary, LATAMEDAI VE.
Under the agreement, LataMed AI and IVIC will collaborate on the design, development, testing, and implementation of a digital interface through which authorized business and institutional users may request available laboratory services, schedule appointments, monitor the status of submitted requests, access approved reports and documentation, and complete authorized payment-related processes. The proposed module is intended to provide a centralized digital workflow for organizations seeking scientific and laboratory services in areas that may include healthcare, pharmaceuticals, food production, agriculture, and related industries. The specific services made available through the platform will be determined by IVIC and implemented in accordance with technical, operational, security, and legal requirements established by the parties.
LataMed AI will begin working with IVIC to define the module's functional requirements, user-access procedures, data architecture, payment workflows, document-management capabilities, and phased testing and implementation process. The parties will also establish appropriate procedures governing the handling, transmission, storage, and authorized access to laboratory-related information and documentation. The contemplated platform functionality may include electronic service requests, appointment scheduling, request-status tracking, secure payment facilitation, and controlled access to laboratory reports or other authorized documentation. The final functionality, implementation schedule, and scope of available services remain subject to continued technical development, testing, and approval by the parties.
“This agreement represents an opportunity to apply our technology to an important area of scientific and enterprise service delivery,” said Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp. “Our objective is to work with IVIC to develop a responsible digital framework that makes it easier for authorized users to request services, manage appointments, monitor processes, and access approved information through a centralized platform.”
Management believes the proposed module may expand LataMed AI's capabilities beyond patient-facing telemedicine by demonstrating how its technology can support institutional and enterprise workflows involving healthcare, scientific services, laboratory coordination, and digital documentation. The initiative is also consistent with the Company’s broader strategy of developing digital infrastructure connecting patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, institutions, and other participants in the healthcare and scientific-services ecosystem. If successfully implemented, management believes the module may provide a framework that could potentially be adapted for other institutional and enterprise service environments in Venezuela and elsewhere in Latin America. Any future expansion would remain subject to separate agreements, technical readiness, applicable regulatory requirements, and the needs of participating institutions.
The agreement establishes the framework under which LataMed AI and IVIC intend to develop and evaluate the proposed module. It does not guarantee a specific implementation date, level of user adoption, service volume, revenue, profitability, or expansion to additional institutions. The Company will provide further updates regarding development, testing, and implementation as appropriate.
This partnership signals LataMed AI's strategic pivot toward institutional and enterprise services, potentially broadening its revenue streams and solidifying its presence in Latin America's scientific and healthcare infrastructure. For additional information, please visit https://latamed.ai or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
